• Select the area you would like to search.
  • ACTIVE INVESTIGATIONS Search for current projects using the investigator's name, institution, or keywords.
  • EXPERTS KNOWLEDGE BASE Enter keywords to search a list of questions and answers received and processed by the ADNI team.
  • ADNI PDFS Search any ADNI publication pdf by author, keyword, or PMID. Use an asterisk only to view all pdfs.



The first phase of ADNI launched in October 2004 with a 6-year, $67 million contributions from the National Institute on Aging, 13 pharmaceutical companies and two foundations. Originally designed to find more sensitive and accurate biomarkers for the early detection and tracking of AD, the ADNI1 study gathered and analyzed thousands of brain scans, genetic profiles, and blood and cerebrospinal fluid biomarkers.

The study included 400 subjects diagnosed with mild cognitive impairment (MCI), 200 subjects with the early AD, and 200 elderly control subjects.

As with all ADNI phases, ADNI1 researchers used brain imaging measures including structural MRI and PET (both FDG-PET, which measures glucose metabolism in the brain, and a pilot study using amyloid PET using a radioactive compound “Pittsburgh Compound B” which measures brain amyloid accumulation).

Further Reading